【Ono Pharmaceutical】Full-Year Financial Results for 2026｜Sales: ¥515.7 billion, Net Income: ¥69.9 billion

Performance Overview

Ono Pharmaceutical's consolidated results for the fiscal year ending March 2026 recorded significant growth, with sales of ¥515.7 billion (up 5.9% YoY), operating income of ¥92.3 billion (+54.4%), and net income of ¥69.9 billion (+39.4%). Despite intensified domestic competition and generic entrants, overall business was strong, driven by increased overseas operations and royalty income. Continued investment in R&D facilitated clinical progress of new drug candidates and strategic partnerships. The outlook for 2027 projects sales of ¥455.0 billion and net income of ¥7.1 billion, with ongoing growth ambitions.

Future Outlook and Investor Impact

While next year's forecast suggests sales will decline approximately 11.8% to ¥455.0 billion, the company will maintain investment in R&D and partnerships to accelerate approval for new drug candidates and expand globally. Dividend payments are planned at ¥80 per share annually, balancing shareholder returns with future investments. The company's solid financial foundation and proactive R&D and collaborations support long-term growth. Investors should focus on Ono Pharmaceutical’s innovative drug development and stable financial status.